original articlesstatistics and clinical trial methodologyThe reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members
statistics and clinical trial methodology
Under an Elsevier user license
open archive
Key words
phase III trial reports
adverse events
grade 5 adverse events
EORTC
CONSORT statement
Cited by (0)
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.